Dynamic Functional Imaging Phenotyping and Disease Progression Risk Assessment in COPD Using Dynamic Chest Radiography: A Multicenter Retrospective Study
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Enrollment
- 2,500
- Locations
- 1
- Primary Endpoint
- Exacerbation/respiratory history and event
Study Overview
Brief Summary
To evaluate the utility of DCR-derived parameters for identifying dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of disease progression in COPD.
Detailed Description
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide. Approximately 100 million people in China have COPD, yet the early diagnosis rate remains below 13%. This multicenter retrospective study will collect previously acquired dynamic chest radiography (DCR) images, pulmonary function test results, chest computed tomography images, symptom scores, clinical data, and follow-up outcomes from participating centers. A standardized multicenter retrospective DCR-COPD database will be established to systematically evaluate the utility of DCR-derived parameters for characterizing dynamic functional imaging phenotypes, assessing disease severity, and predicting the risk of COPD progression. The study will also provide a foundation for model development and subsequent prospective multicenter validation.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 30 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged 30-85 years.
- •Male or female.
- •Patients who underwent pulmonary function testing and dynamic chest radiography at the hospital.
Exclusion Criteria
- •Incomplete medical records.
- •Considered unsuitable for inclusion in the study at the investigator's discretion.
Arms & Interventions
COPD group
any patient who complains of dyspnea, chronic cough or sputum, a history of recurrent lower respiratory infection and/or a history of exposure to disease risk factors, Pulmonary function examination indicated that FEV1/FVC <0.7 after bronchodilator was used to confirm COPD.
PRISM group
After bronchial dilation, FEV1/FVC was ≥0.70, and FEV1%PRED was <80%.
Smoking exposure groups
Smoking history of 10 years, or without COPD, pulmonary function of COPD diagnosis standard.
Normal control group
Never-smokers without airflow limitation and with normal pulmonary function.
Outcomes
Primary Outcomes
Exacerbation/respiratory history and event
Time Frame: At Baseline
Measurement of disease control and burden
FEV1 %
Time Frame: At Baseline
Measurement of lung function
FEV1 /FVC
Time Frame: At Baseline
Measurement of lung function
Emphysema
Time Frame: At Baseline
Measurement of chest CT
diaphragm movement
Time Frame: At Baseline
Measurement of Dynamic chest radiograph
lung field area
Time Frame: At Baseline
Measurement of Dynamic chest radiograph
lung field area change rate
Time Frame: At Baseline
Measurement of Dynamic chest radiograph
CAT
Time Frame: At Baseline
Measurement of questionnaires
SGRQ
Time Frame: At Baseline
Measurement of questionnaires
mMRC
Time Frame: At Baseline
Measurement of questionnaires
Smoking history and status
Time Frame: At Baseline
Risk factors of COPD development or lung function decline
Secondary Outcomes
No secondary outcomes reported